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Abstract
Environmental health research is a relatively new scientific area with much interdisciplinary
collaboration. Regardless of which human population is included in field studies (e.g., general
population, working population, children, elderly, vulnerable sub-groups, etc.) their conduct must
guarantee well acknowledged ethical principles. These principles, along with codes of conduct, are
aimed at protecting study participants from research-related undesired effects and guarantee
research integrity. A central role is attributed to the need for informing potential participants (i.e.,
recruited subjects who may be enrolled in a study), obtaining their written informed consent to
participate, and making them aware of their right to refuse to participate at any time and for any
reason. Data protection is also required and communication of study findings must respect
participant's willingness to know or not know. This is specifically relevant for studies including
biological markers and/or storing biological samples that might be analysed years later to tackle
research objectives that were specified and communicated to participants at the time of
recruitment or that may be formulated after consent was obtained.
Integrity is central to environmental health research searching for causal relations. It requires open
communication and trust and any violation (i.e., research misconduct, including fabrication or
falsification of data, plagiarism, conflicting interests, etc.) may endanger the societal trust in the
research community as well as jeopardize participation rates in field projects.
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Note
"...a moltitudine de' veri concorre all'investigazione, accresci-
mento e stabilimento delle discipline, e non alla diminuzione o
destruzione,...'
''...the multitude of known truths stimulates the investigation,
growth, and establishment of the disciplines, not their diminu-
tion or destruction,...''
Galileo Galilei
Lettera a Cristina di Lorena, Granduchessa Madre di Toscana.
Opere, Edizione Nazionale a cura di Antonio Favaro, Giunti-
Barbera, Firenze 1968, vol. 5, pp. 309-348.
Environmental health research
Why is scientific integrity important in environmental 
health research
The field of environmental health science [1], is an inter-
disciplinary field, a discipline requiring cooperation
between scientists trained in different fields, from basic
science (e.g., biology, physics) to toxicology, industrial
hygiene, occupational health, epidemiology, analytical
and organic chemistry, statistics, and molecular biology.
Environmental health interacts with social, political and
economical forces and may have a high social and eco-
nomic impact, which in turn leads to pressure on the sci-
entists working in the area [1]. Because of this it is
important to actively foster objective, independent, and
rigorous scientific work to enhance our understanding of
environmental health. As for clinical research, environ-
mental science requires open communication and trust
and any violation against scientific integrity may endan-
ger the societal trust in the research community and even-
tually jeopardize participation rates in field projects. It
may also affect seriously the public-science trustful rela-
tionship and preclude lay people from participation in
research so that studies may not be any more representa-
tive of the target population.
Ethics within and between research groups
Good scientific practice in large epidemiological health
studies is supported by good communication between
and within the research groups with everybody carrying
the responsibility also of the original data (at least by
knowing how it was collected, where it is stored, and how
it has been used for conclusions). This is not as self-evi-
dent as one might assume judging by the recent examples
of revealed fraud cases [2,3]. Especially a case of Jon
Sudbo [4,5], who's publications were proven to be invalid
because of the fabrication and manipulation of data,
revealed the possibility to misuse of colleagues in such
cases through international collaboration. In addition to
the real harm to colleagues, the results of data falsification
are manifold from distracting the scientific community
from real research priority, diverting public agency funds
from useful to useless research programmes, affecting reg-
ulatory standards, undermining trust on research, and, at
the personal level, meaning the end of a career along with
possible application of penalties [6,7]. Data fabrication
and falsification may appear also in documents submitted
to funding agencies to obtain research grants in addition
to papers in scientific journals or presented at public
meeting or used as scientific evidence in patent applica-
tion [8]. In all these cases greed for money and fame has
overruled scientific integrity and damaged trust on collab-
orators which is essential in scientific community to carry
out large studies. In epidemiological studies the effect of a
poor design cannot be corrected through statistical analy-
sis. Therefore, cooperation with statisticians is important
already at the planning stage with identification of the
study design and the preparation of the written study pro-
tocol. A clear differentiation between aims and hypothe-
ses formulated before data collection, and analysis and
interpretation of the study findings and their publication
thereafter, central to science, should be agreed within the
whole group carrying out the research. Stating the biolog-
ical relationships under investigation, the main and sec-
ondary research hypotheses, identifying the target
population and the study samples, and the statistical
methods to be used for formal hypothesis testing is essen-
tial. Collaboration already at this stage also helps to pre-
vent potential selective data censoring and torturing [9].
The larger the project is the more contributors there are
leading to higher number of authors especially in multi-
disciplinary studies. Currently, a small minority of
research papers are written by one author only [10]. At the
publication phase the question of authorship may
become a controversy within a multidisciplinary research
project [10]. The practices vary between disciplines and no
general guidelines exist except that each author must have
participated in each stage of research enough to deserve
authorship and be responsible for the content of the paper
[10,11]. To avoid difficulties at the publication stage, it is
recommendable to plan for publication policy already at
the stage of planning [11,12]. Erlen and coworkers [11]
present an example of such guideline of authorship and
stress the importance of including resolution of conflicts
to be included.
Scientific integrity
What is scientific integrity?
Integrity has been defined as "a steadfast adherence to a
strict moral or ethical code" [13]. According to the Insti-
tute of Medicine (IOM) for the individual scientist, "integ-
rity embodies above all a commitment to intellectual honesty
and personal responsibility for one's actions and to a range of
practices that characterize responsible research conduct. It is an
aspect of moral character and experience." Within a research
institution, integrity is "a commitment to creating an envi-Environmental Health 2008, 7(Suppl 1):S9 http://www.ehjournal.net/content/7/S1/S9
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ronment that promotes responsible conduct" [14]. Clearly,
both the individual investigators and the research envi-
ronment are expected to act with integrity to guarantee sci-
entific standards of excellence, trustworthy research
findings, and to preserve public confidence in biomedical
sciences.
The integrity of science is intrinsic to the scientific method
and consists of a set of principles and tools aimed at
ensuring unbiased testing of scientific theories (e.g., study
hypothesis). The foundation of the scientific methods is
the "hypotheses statement and testing": when possible
explanations of a phenomenon are proposed, experimen-
tal studies are required to test these hypotheses. It follows
that other scientists in independent research settings
should be able to replicate the findings of a given study
within the variability allowed by random or systematic
measurement errors. Indeed, repeating the experiments is
a commonly accepted research practice. Failure to repli-
cate specific findings may question or disprove the
hypothesis. In this process honesty and trust on fellow sci-
entists is taken as self-evident. Fraudulent behavior, when
found, always leads to the end of career. Unfortunately, it
also affects the trust of public for science which is a prereq-
uisite for participation, and is required to finance research
and to make use of research findings in society [15].
Several types of inappropriate behavior have been identi-
fied as capable of undermining research integrity [16],
most of which fall into the following areas: unethical
treatment of research subjects, fabrication and/or falsifica-
tion of data, plagiarism, and failure to disclose conflict of
interest. These practices apply to all typical phases of bio-
medical research: proposing the study hypothesis and the
methods for scientific approval, competing for funding,
conducting the research and the formal statistical analyses
which have been declared in the research protocol, inter-
preting and reporting the findings. They also apply to the
many roles undertaken by most scientists who may act
contemporarily as researchers, research reviewers for
funding agencies and or scientific journal, members of
institutional review boards, research ethics committees,
governmental bodies, national or international commit-
tees, consultants for chemical or drug companies and con-
sultancy firms, or present expert testimonies at trials. Their
participation in the field of biomedical research results in
a complex net of connections and relationships that
extend well beyond the field of science with their aims
(i.e., the advancement of knowledge, promotion of health
and well-being), with public health, regulatory and legal
implications.
Ethical treatment of study participants and their biological 
specimens
Biomedical research has to apply the well acknowledged
ethical principles concerning people who participate in
biomedical scientific studies. These principles were iden-
tified some 50 years ago [17] and have been developed
further [18,19] to meet the needs of the fast growing,
evolving biomedical field. The principles are aimed at
protecting study participants from research-related
adverse-effects and guarantee research integrity. Within
this ethical framework, scientists have an obligation to
study subjects as well as their biological specimens [20]
and must conform to the ethics of the medical profession
to satisfy moral, ethical and legal concepts. In order to
meet ethical standards, environmental health research
must be socially and scientifically valuable. Only scientif-
ically valid research can provide, what is expected from
environmental health research as a branch of biomedi-
cine: sound scientific evidence for primary prevention.
For epidemiological environmental health research the
establishment and use of large biobanks would be very
useful and various efforts in that direction over the past 10
years have been initiated [21]. With such initiatives, the
ethical aspects, especially those in connection with the
ethical treatment of donators and their samples, have
emerged. The idea of a biobank is to systematically collect
and store identifiable biological material or samples from
which protein, DNA and other elements can be isolated,
and then connect biological data with individual data
about health and life-style. This is not possible without an
extensive use of information technology which may
endanger privacy [22]. The discussion of almost all other
ethical aspects, e.g. management of biobanks, informed
consent issues and financial aspects are linked to the pri-
vacy issue [23].
The principle of autonomy and the informed consent
Important aspects of autonomy are informing potential
participants (i.e., recruited subjects who may be enrolled
in a study), obtaining their written truly informed consent
to participate, and making them aware of their right to
refuse to participate at any time and for any reason. How-
ever, this is not sufficient for autonomy. Study partici-
pants should also have the right to privacy both as to data
protection and whether to know their own results if any
clinical or experimental assay is performed as part of the
research protocol. This is especially relevant for studies
including vulnerable subjects (e.g., children, impaired
people), measuring biological markers, and/or storing
identifiable biological specimens (biobanking). Samples
from biobanks may be analyzed years later to tackle
research objectives that were specified and communicated
to participants at the time of recruitment or that may be
formulated after consent was obtained. Rules securingEnvironmental Health 2008, 7(Suppl 1):S9 http://www.ehjournal.net/content/7/S1/S9
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recovery of samples, but also preventing potential misuse
need to be set up. The Data Protection Directive [24] states
that safe handling of keys for sample codes must be
assured by minimising the number of persons with access
to this information. In the case samples are forwarded to
other institutions it would be advisable to keep the code
at the sample collector and/or double code the samples.
As stated in the pharmacogenetics terminology paper
developed by the European Medicines Agency, long term
storage of identifiable samples enabling follow-up studies
is necessary for full term development of safety assess-
ment of medicines [25].
Thus the Agency recommends broader scopes of the
informed consent and keeping identification of study per-
sons but data protection by double coding. Obtaining a
truly informed consent is quite complicated when vulner-
able subjects and people with diminished capacity of self-
determination (i.e., limited autonomy) are recruited. This
is especially the case with children whose ability to con-
sent is age dependent, being related to physical, mental,
and psychological development [26]. Indeed, children
may not be fully capable of understanding complex bio-
medical research issues. It follows that no true consent can
be obtained from children during their gestational life
and during their infanthood. However, children from the
age of 3–4 can already be explained using proper lan-
guage, what will be going on, and assent may be obtained.
Parental advice with their informed permission along
with the child's assent is the right of children and fulfils
the autonomy [26,27]. Such a principle includes the right
of the child to opt out when legally adult.
This is most relevant for the EU-biomonitoring program
where samples from different exposure groups may pro-
vide useful information about past exposures to hitherto
unknown exposures to new compounds. Some argue that
such new studies need not only a renewed ethics approval
but also a new informed consent from the participant
[28]. For the biomonitoring programs a system ensuring
optimal use of samples is needed – it can be argued that it
is not ethically justifiable to collect new samples if suita-
ble samples exist in a biobank. How this can be accom-
plished without violating the autonomy of the study
participants to decide current and future use of their sam-
ples has not been resolved. As a pragmatic solution a
broad informed consent (prospective consent) for the
core study and future uses approved by an ethics commit-
tee has been proposed [29,30].
Studies on children are scientifically justified by a possibly
increased susceptibility of children (and fetuses) to envi-
ronmental genotoxic and immunotoxic agents [31]. By
comparing groups with different exposures to common
environmental pollutants (e.g., mainstream and environ-
mental tobacco smoke, food, ground and water contami-
nants) and with different susceptibilities to such
pollutants, the knowledge of the risk posed by environ-
mental exposures is expected to be enhanced. Conse-
quently, age-specific regulatory actions may be
established based on the identification of safety levels for
children.
Research misconduct
What constitutes research misconduct
Cases of misconduct in medical sciences have been docu-
mented and concern both clinical and environmental
research [32-38]. Although misconduct is a term com-
monly used to describe deviant scientific behavior, it is
difficult to define, and there has been pressure to use a
definition which is the "lowest common denominator" of
the term: fabrication, falsification and plagiarism, but to
leave out e.g. misbehavior and waste [39,40]. In this con-
text it is important to realize that fraud is never the first
step fraudulent scientists do, as Check (2002) reminds
[41]. Getting away with small unethical deeds may lead to
bigger issues. At the other end is a strict regulation of sci-
entific community. Richman and Richman (2007) pro-
pose an approach for preventive measures simulating
those in commercial companies [42]. However, this could
lead to structures that paralyze innovative research (all
methods, data and processes audited by external bodies)
but at the end fail to rule out scientific misconduct,
because no one person could be responsible as an
"accountable scientist" for research integrity, as they pro-
pose.
In 1999, a consensus statement of the Council of Science
Editors (CSE) provided a broad definition of research mis-
conduct: behavior by a researcher, intentional or not, that falls
short of good ethical and scientific standard [43]. The result of
such a behavior can affect research to the extent that the
findings reported by a researcher no longer reflect the
observed truth [44], data publication is intentionally
deferred [45], or suppressed [33,46]. CSE refined the def-
inition of misconduct in 2002 by specifying that two con-
cepts are central to scientific misconduct: deceit and
negligence [20] and excluding honest errors from the def-
inition. Such a position is based on the Medical Research
Council's policies and procedures for inquiring into alle-
gations of scientific misconduct [47] and the guidelines of
the largest biomedical charity in the UK, the Wellcome
Trust, which does not consider honest error or differences
in the design, conduct and interpretation or judgment in
evaluating research methods or findings a misconduct
[48]. In other words, only if poor-quality methods are
used with the intention to deceive or without regard to
patients' safety, researchers' behavior can be considered
not conforming to prevailing standards. All the other
cases of poor-quality research are simply considered asEnvironmental Health 2008, 7(Suppl 1):S9 http://www.ehjournal.net/content/7/S1/S9
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poor science. Does this imply that poor-quality science
can be funded and published? Actually an important
aspect that research ethics committees have scrutinized is
the very quality of the research with the understanding
that it would be waste of public money to carry out poor
research.
It is clear that there is an urgent need for a clear definition
of misconduct considering that individual researchers,
institutions, funding agencies, journals, scientific socie-
ties, governments, the society components such as health
and environmental priorities, and, last but not least, the
public trust in science are all dependent on scientific
integrity[14,49]. It seems clear also that any operational
definition identifying faulty behaviors, including a pre-
liminary taxonomy already available [50] is subjected
inevitably to continuous reviews according to the devel-
opment of science as well as ethics of science [51,52]. The
variability and the lack of consistency of the definitions of
behaviors constituting misconduct [40,50,53] are of no
help to researchers worldwide. It is within this complex
scenario that the First World Conference on Research
Integrity organized by the European Science Foundation
(ESF) and the US Department of Health and Human Serv-
ices, Office of Research Integrity (ORI) was held in Lisbon,
Portugal on 16 to 19 September 2007 [54]. The ESF-ORI
Conference has focused attention on the lack of agree-
ment on key elements of research behavior and wide var-
iation implementing research policies reported between
countries and organizations "in order to retain public confi-
dence and to establish a clear best practice frameworks at an
international level" [2,54].
Fabrication and or falsification of data
Data fabrication means making up data or other relevant
information at any stage of the typical scientific process
spanning from research development and application for
funding, up to the submission of findings for publication
[20]. Falsification indicates alterations or intended misin-
terpretation of the true evidence of experimental or obser-
vational studies. Falsification is in a continuum state with
the process of data selection, the latter implying declared
and defendable criteria based on the aims of a given
research and the statistical methods identified to test main
and secondary hypothesis as stated in the written research
protocol. Falsification is perpetrated when data selection,
is carried against or without any scientific or statistical jus-
tification. Data fabrication and falsification are punisha-
ble, when there is evidence that false information are
incorporated into official document that are submitted to
funding agencies to obtain research grants, scientific jour-
nals to disseminate knowledge, when they are presented
at public meeting or used as scientific evidence in patent
application. The results of data falsification may be mani-
fold from distracting the scientific community from real
research priority, diverting public agency funds from use-
ful to useless research programmes, affecting regulatory
standards, undermining trust on research, and, at the per-
sonal level, meaning the end of a career along with possi-
ble application of penalties [6-8,55].
Plagiarism
Intentionally using other's people thoughts, ideas, or
words is considered plagiarism. It is a violation of the eth-
ical principle of failing to reveal and crediting an existing
source (a practice that dates back to Euclid, 300 BC) by
proposing as one's own idea when it truly belongs to
someone else. It is a matter of false attribution. Self plagia-
rism is also considered ethically unacceptable: it occurs
when one uses he's own previously published work (or
parts of it) without citing any source. Self plagiarism
rather than being strictly an issue of false attribution is
generally a way of increasing someone's scientific produc-
tion by attempting to repeatedly publish copies of one's
own research findings or papers in different scientific
journals. Although scientific journals' publication policy
requires that a paper can be submitted for publication to
a single journal [56], redundant publication appears to be
a serious problem in biomedical sciences with the fre-
quency of duplicate publication ranging between little
less than 10% and 14% [57,58]. Plagiarism in biomedical
research may be reduced by collaboration and multiple
authorship and prevented by implementing the practice
of mentoring within research teams and research institu-
tion [59].
Failure to disclose conflict of interest (CoI)
A conflict of interest (CoI) arises when an individual's
interests may compromise communications to research
subjects, research reports (dissemination) [60], and in sit-
uations when a researcher has competing personal obliga-
tions or financial interests that would interfere with a
researcher objectivity or when a reviewer has an interest in
a grant application that is likely to result in a biased
review. Therefore, CoI can occur in any situation in which
there is increased potential for the violation of the
accepted norms governing responsible research conduct
and the professional obligations and commitments to
universities or research institutions. Friedman [61]
attributes to CoI "an erosive effect on trust in science",
capable of undermining the society trustful attitude
toward science (i.e., scientists and research findings). The
importance of knowing conflict of interest information
(transparency) is considered relevant by the majority of
potential research participants, with 64% to 87% of them
indicating that financial CoI should be disclosed as part of
informed consent [62,63]. Indeed, CoI has been shown to
significantly interfere with researchers' objectivity in envi-
ronmental health research [64]. Examination of 106
review articles on passive smoking showed that the authorEnvironmental Health 2008, 7(Suppl 1):S9 http://www.ehjournal.net/content/7/S1/S9
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affiliation with the tobacco industry was the only factor
associated with the conclusion against the evidence that
exposure to passive smoking is associated with health
risks [64]. The practice of funding academic scientists
through  ad hoc created industry-supported research
projects lacking independency is well known [65]. The
result of such misconduct is a seriously biased piece of sci-
entific evidence undermining public trust in science and
precluding or postponing effective preventive actions
[66]. These twofold implications require that full trans-
parency and accountability is enforced within research
institutions and research funding agencies to ensure that
potential conflict of interest do not arise or are effectively
managed. The role played by each party in the generation,
reporting and interpretation of research findings must be
clearly stated to enable the scientific community as well as
the general public understanding the relationship
between individual investigators, academic institutions,
private and public funding agencies, and industry.
Recently a perception study of mothers donating placen-
tas for experimental research showed general trust in
research, with face-to-face interaction, written informa-
tion material and informed consent forms playing an
important role in creating trusting relationships in medi-
cal research [63].
In most European regulations regarding research ethics
committees the applicant is asked to include information
about potential conflicts of interests. A CoI should be
declared also during the evaluation of research projects
submitted for funding to the European Commission
Research Framework Programmes. Since an unbiased
evaluation of research projects is required, the appointed
independent experts have to sign a declaration certifying
that they have no conflict of interest at the time of
appointment and that they will inform the Commission if
any CoI should arise [67].
The U.S. National Institutes of Health, Office of Extramu-
ral Research has established regulations to ensure that
Government employees, scientific reviewers, or others
having the ability to influence funding decisions have no
personal interest in the outcome of a review process of any
NIH-supported investigation. Reviewers are required to
certify that they have disclosed all conflicts of interest they
may have with the research applications or contract pro-
posals [68,69].
Fostering research integrity: the role of study design
The most critical step in any research is the identification
of the study design and the preparation of the written
study protocol. The written research protocol is the start-
ing point for good quality research allowing a peer review
process by institutional review boards and research ethics
committees [70]. According to the document prepared for
the International Epidemiology Association Council
meeting held in Brazil, April, 2007, [71] "the research pro-
tocol is the cornerstone of an epidemiological research
project, where the purpose of the study, the hypotheses,
the design, the source population, and the planned anal-
yses are described". It is an indisputable fact that it must
provide the evidence for the need and feasibility of a
research project, a detailed description of the investigation
plans, including a clear definition of the study aims and
outcomes (e.g., the biological relationships under exami-
nation) and the a priori hypotheses to be tested within the
study along with ethical considerations. These are formu-
lated before the data are collected on the basis of the avail-
able scientific evidence as well as the research team
experience. A clear differentiation between aims and
hypotheses formulated before data collection, and analy-
sis and interpretation of the study findings and their pub-
lication thereafter, is central to science. Stating the
biological relationships under investigation, the main and
secondary research hypotheses, identifying the target pop-
ulation and the study samples, and the statistical methods
to be used for formal hypothesis testing is essential. The
written research protocol is used by the investigators as a
reference tool throughout the study conduct. It prevents
potential research misconduct including selective data
censoring and torturing (meaning that study data, can be
manipulated to prove whatever the investigator likes to
prove) [9]. Censoring data to prove or disprove a given
hypothesis and torturing data to generate fashionable
(statistical) associations of potential biological relevance
(deserving further studies and then further funding), can
easily be generated from datasets in the absence of a priori
declared hypotheses or when a study protocol fails to
identify primary and ancillary hypotheses. Negative find-
ings, not supporting the main hypothesis, may result from
studies that have not been carefully planned with respect
to the number of subjects (i.e., observations) required to
efficiently test, statistically, the hypothesis being investi-
gated (i.e., a study with a low statistical power). A study
protocol lacking statistical power calculation should not
obtain ethical clearance and should not be considered by
funding agencies. Moreover, it is important to keep in
mind, during the planning phase of a new investigation,
that the effect of a poor design cannot be corrected
through statistical analysis and that the regular practice of
cooperating with statisticians is recommended. Sub-
groups analyses (fractionating data), which is usually seen
as a way to producing negative results, will almost inevita-
bly result in statistically non significant findings which
cannot be interpreted as supportive of the evidence
against a study null hypothesis, simply being the result of
an inadequate sample size.Environmental Health 2008, 7(Suppl 1):S9 http://www.ehjournal.net/content/7/S1/S9
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Conclusion
Integrity is central to environmental health research
searching for causal relations and requires open commu-
nication and trust. Any violation (e.g., data fabrication
and falsification, redundant publications, plagiarisms,
and undisclosed financial conflict of interest) may endan-
ger the societal trust in the research community. Environ-
mental health research is expected to be scientifically
justified, with sound research questions and valid study
protocols with sufficient statistical power in epidemiolog-
ical studies. A clear definition of the study aims and out-
comes, of the sample size required to test the  a priori
identified main hypothesis of this study (according to the
defined statistical plan), represents a guarantee for the
study conduct and the interpretation of the findings.
Regardless of which human population is included in
human studies (e.g., general population, working popula-
tion, children, elderly, vulnerable sub-groups, etc.) their
treatment according to well acknowledged ethical princi-
ples must be guaranteed. These principles are aimed at
protecting study participants from research-related unde-
sired effects. Study subjects, as well as their biological
specimens, and all individual data collected or generated
within a study need to be handled in a way that potential
physical, mental or social harm can be avoided. Central
issues include informing persons being asked to partici-
pate in a study, obtaining a written informed consent to
participate from those wanting to enrol, and making them
aware of their right to refuse or to retract at any time and
for any reason. Special ethical aspects arise when children
(including newborns) are enrolled in field studies. Given
their lack of autonomy up to a certain age there is a need
for obtaining their assent together with the permission
from their parents or guardians to enrol them in any
research. In addition, they should be able to withdraw the
consent when they grow older. All these various aspects,
but especially the question of privacy, are elemental when
establishing and using biobanks, a necessity in environ-
mental health research.
It is the task of us, scientists, to create an atmosphere of
trust within the scientific community and more widely in
society to be able to establish such biobanks. Strict
research integrity, honored by all individual scientists as
well as the research community on the whole is the start-
ing point. In addition, justification to public for environ-
mental research is important for people to commit
samples and health information, and honors the auton-
omy of people.
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